Abstract
The sphingosine 1 phosphate receptor family has been studied widely since the initial discovery of its first member, endothelium differentiation gene 1. Since this initial discovery, the family has been renamed and the primary member of the family, the S1P1 receptor, has been targeted for a variety of disease indications and successfully drugged for the treatment of patients with relapsing multiple sclerosis. Recently, the three-dimensional structure of the S1P1 receptor has been determined by X-ray crystallography and the specifics of the sphingosine 1 phosphate ligand binding pocket mapped. Key structural features for the S1P1 receptor will be reviewed and the potential binding modes of additional pharmacologically active agents against the receptor will be analyzed in an effort to better understand the structural basis of important receptor–ligand interactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arnon TI, Xu Y, Lo C et al (2011) GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333:1898–1903. doi:10.1126/science.1208248
Berst F, Grosche P, Janser P, Zecri F (2007) Biaryl sulfonamide derivatives. US Patent Office US 20100029609
Brinkmann V (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21457. doi:10.1074/jbc.C200176200
Brinkmann V, Pinschewer DD, Feng L, Chen S (2001) FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 72:764–769
Caffrey M (2000) A lipid’s eye view of membrane protein crystallization in mesophases. Curr Opin Struct Biol 10:486–497
Cahalan SM, Gonzalez-Cabrera PJ, Nguyen N et al (2013) Sphingosine 1-phosphate receptor 1 (S1P1) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P1 antagonist. Mol Pharmacol 83:316–321. doi:10.1124/mol.112.082958
Cahalan SM, Gonzalez-Cabrera PJ, Sarkisyan G et al (2011) Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice. Nat Chem Biol 7:254–256. doi:10.1038/nchembio.547
Cherezov V (2011) Lipidic cubic phase technologies for membrane protein structural studies. Curr Opin Struct Biol 21:559–566. doi:10.1016/j.sbi.2011.06.007
Cherezov V, Rosenbaum DM, Hanson MA et al (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258–1265. doi:10.1126/science.1150577
Chien EYT, Liu W, Zhao Q et al (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330:1091–1095. doi:10.1126/science.1197410
Choi JW, Herr DR, Noguchi K et al (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50:157–186. doi:10.1146/annurev.pharmtox.010909.105753
Chun J, Goetzl EJ, Hla T et al (2002) International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54:265–269
Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415. doi:10.1056/NEJMoa0907839
Coste O, Brenneis C, Linke B et al (2008) Sphingosine 1-phosphate modulates spinal nociceptive processing. J Biol Chem 283:32442–32451. doi:10.1074/jbc.M806410200
Cuvillier O, Pirianov G, Kleuser B et al (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381:800–803. doi:10.1038/381800a0
Davis MD, Clemens JJ, Macdonald TL, Lynch KR (2005) Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 280:9833–9841. doi:10.1074/jbc.M412356200
Deng Q, Clemas JA, Chrebet G et al (2007) Identification of Leu276 of the S1P1 receptor and Phe263 of the S1P3 receptor in interaction with receptor specific agonists by molecular modeling, site-directed mutagenesis, and affinity studies. Mol Pharmacol 71:724–735. doi:10.1124/mol.106.029223
Fernandez O, Pozzilli C, Freedman M, et al. (2012) Pharmacodynamic effect, safety and tolerability of ponesimod, a selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis. ECTRIMS
Filipek S, Stenkamp RE, Teller DC, Palczewski K (2003) G protein-coupled receptor rhodopsin: a prospectus. Annu Rev Physiol 65:851–879. doi:10.1146/annurev.physiol.65.092101.142611
Fredriksson R, Lagerström MC, Lundin L-G, Schiöth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256–1272. doi:10.1124/mol.63.6.1256
Fujii Y, Hirayama T, Ohtake H et al (2012a) Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities. J Immunol 188:206–215. doi:10.4049/jimmunol.1101537
Fujii Y, Ohtake H, Ono N et al (2012b) Lymphopenia induced by a novel selective S1P1 antagonist structurally unrelated to S1P. Biochim Biophys Acta Mol Cell Biol Lipids 1821:600–606. doi:10.1016/j.bbalip.2011.12.006
Fujii Y, Ueda Y, Ohtake H et al (2012c) Blocking S1P interaction with S1P1 receptor by a novel competitive S1P1-selective antagonist inhibits angiogenesis. Biochem Biophys Res Commun 419:754–760. doi:10.1016/j.bbrc.2012.02.096
Fujita T, Inoue K, Yamamoto S et al (1994) Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 47:208–215
Fyrst H, Saba JD (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6:489–497. doi:10.1038/nchembio.392
Gergely P, Wallstrom E, Nuesslein-Hildesheim B, et al. (2009) Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. ECTRIMS
Gonzalez-Cabrera PJ, Jo E, Sanna MG et al (2008) Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 74:1308–1318. doi:10.1124/mol.108.049783
Granier S, Manglik A, Kruse AC et al (2012) Structure of the δ-opioid receptor bound to naltrindole. Nature 485:400–404
Gräler MH, Goetzl EJ (2004) The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18:551–553. doi:10.1096/fj.03-0910fje
Haga K, Kruse AC, Asada H et al (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:547–551. doi:10.1038/nature10753
Hanson MA, Roth CB, Jo E et al (2012) Crystal structure of a lipid G protein-coupled receptor. Science 335:851–855. doi:10.1126/science.1215904
Hanson MA, Stevens RC (2009) Discovery of new GPCR biology: one receptor structure at a time. Structure 17:8–14. doi:10.1016/j.str.2008.12.003
Hartung J, Olson A, Peach RJ, et al. (2013) Results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist, in healthy adult volunteers. ECTRIMS
Healy LM, Sheridan GK, Pritchard AJ et al (2013) Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes. Br J Pharmacol 169:1114–1129. doi:10.1111/bph.12207
Hla T, Maciag T (1990) An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 265:9308–9313
Hobson JP, Rosenfeldt HM, Barak LS et al (2001) Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291:1800–1803. doi:10.1126/science.1057559
Holdsworth G, Osborne DA, Pham TT et al (2004) A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor. BMC Biochem 5:12. doi:10.1186/1471-2091-5-12
Hollenstein K, Kean J, Bortolato A et al (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499:438–443. doi:10.1038/nature12357
Hurst DP, Grossfield A, Lynch DL et al (2010) A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 285:17954–17964. doi:10.1074/jbc.M109.041590
Hurst DP, Schmeisser M, Reggio PH (2013) Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations. Chem Phys Lipids 169:46–56. doi:10.1016/j.chemphyslip.2013.01.009
Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K (2000) Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485:63–99
Huwiler A, Pfeilschifter J (2008) New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 75:1893–1900. doi:10.1016/j.bcp.2007.12.018
Ibrahim MA, Johnson HWB, Jeong JW et al (2012) Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists. J Med Chem 55:1368–1381. doi:10.1021/jm201533b
Inagaki Y, Pham TT, Fujiwara Y et al (2005) Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors. Biochem J 389:187–195. doi:10.1042/BJ20050046
Ishii M, Egen JG, Klauschen F et al (2009) Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458:524–528. doi:10.1038/nature07713
Jaakola V-P, Griffith MT, Hanson MA et al (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211–1217. doi:10.1126/science.1164772
Jo E, Sanna MG, Gonzalez-Cabrera PJ et al (2005) S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 12:703–715. doi:10.1016/j.chembiol.2005.04.019
Kappos L, Radue E-W, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401. doi:10.1056/NEJMoa0909494
Katritch V, Cherezov V, Stevens RC (2012) Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 33:17–27. doi:10.1016/j.tips.2011.09.003
Kenakin T (2012) The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol Toxicol 13:3. doi:10.1186/2050-6511-13-3
Kenakin T, Onaran O (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23:275–280
Kruse AC, Hu J, Pan AC et al (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482:552–556. doi:10.1038/nature10867
Kułakowska A, Żendzian-Piotrowska M, Baranowski M et al (2010) Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci Lett 477:149–152. doi:10.1016/j.neulet.2010.04.052
LaMontagne K, Littlewood-Evans A, Schnell C et al (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66:221–231. doi:10.1158/0008-5472.CAN-05-2001
Landau EM, Rosenbusch JP (1996) Lipidic cubic phases: a novel concept for the crystallization of membrane proteins. Proc Natl Acad Sci 93:14532–14535
Li Z, Chen W, Hale JJ et al (2005) Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3. J Med Chem 48:6169–6173. doi:10.1021/jm0503244
Lim H-S, Park J-J, Ko K et al (2004) Syntheses of sphingosine-1-phosphate analogues and their interaction with EDG/S1P receptors. Bioorg Med Chem Lett 14:2499–2503. doi:10.1016/j.bmcl.2004.03.001
Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346–349. doi:10.1126/science.1070238
Manglik A, Kruse AC, Kobilka TS et al (2012) Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485:321–326. doi:10.1038/nature10954
Napoli KL (2000) The FTY720 story. Ther Drug Monit 22:47–51
O’Sullivan C, Dev KK (2013) The structure and function of the S1P1 receptor. Trends Pharmacol Sci 34:401–412. doi:10.1016/j.tips.2013.05.002
Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604–616. doi:10.1038/nrc1411
Oo ML, Chang S-H, Thangada S et al (2011) Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest 121:2290–2300. doi:10.1172/JCI45403
Oo ML, Thangada S, Wu M-T et al (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282:9082–9089. doi:10.1074/jbc.M610318200
Paik JH, Ss Chae, Lee MJ et al (2001) Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem 276:11830–11837. doi:10.1074/jbc.M009422200
Palczewski K, Kumasaka T, Hori T et al (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739–745
Parrill AL, Baker DL, Wang DA, et al. (2000a) Structural features of EDG1 receptor‐ligand complexes revealed by computational modeling and mutagenesis. Ann N Y Acad Sci 905:330–339. doi: 10.1111/j.1749-6632.2000.tb06573.x
Parrill AL, Tigyi G (2013) Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions. Biochim Biophys Acta 1831:2–12. doi:10.1016/j.bbalip.2012.09.002
Parrill AL, Wang D, Bautista DL et al (2000b) Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J Biol Chem 275:39379–39384. doi:10.1074/jbc.M007680200
Pham T-CT, Fells JI, Osborne DA et al (2008a) Molecular recognition in the sphingosine 1-phosphate receptor family. J Mol Graphics Modell 26:1189–1201. doi:10.1016/j.jmgm.2007.11.001
Pham THM, Okada T, Matloubian M et al (2008b) S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28:122–133. doi:10.1016/j.immuni.2007.11.017
Pyne NJ, Pyne S (2010) Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10:489–503. doi:10.1038/nrc2875
Quancard J, Bollbuck B, Janser P et al (2012) A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol 19:1142–1151. doi:10.1016/j.chembiol.2012.07.016
Rasmussen SGF, Choi H-J, Fung JJ et al (2011a) Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 469:175–180. doi:10.1038/nature09648
Rasmussen SGF, DeVree BT, Zou Y et al (2011b) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477:549–555. doi:10.1038/nature10361
Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S (2009) Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78:743–768. doi:10.1146/annurev.biochem.78.072407.103733
Rosen H, Stevens RC, Hanson M et al (2013) Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem. doi:10.1146/annurev-biochem-062411-130916
Rosenbaum DM, Cherezov V, Hanson MA et al (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318:1266–1273. doi:10.1126/science.1150609
Saha AK, Yu X, Lin J et al (2010) Benzofuran derivatives as potent, orally active S1P1 receptor agonists: a preclinical lead molecule for MS. ACS Med Chem Lett 2:97–101. doi:10.1021/ml100227q
Sanna MG, Liao J, Jo E et al (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839–13848. doi:10.1074/jbc.M311743200
Sanna MG, Wang S-K, Gonzalez-Cabrera PJ et al (2006) Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2:434–441. doi:10.1038/nchembio804
Schadel SA, Heck M, Maretzki D et al (2003) Ligand channeling within a G-protein-coupled receptor. The entry and exit of retinals in native opsin. J Biol Chem 278:24896–24903. doi:10.1074/jbc.M302115200
Schmouder R, Hariry S, David OJ (2012) Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol 68:355–362. doi:10.1007/s00228-011-1146-9
Schürer SC, Brown SJ, Gonzalez-Cabrera PJ et al (2008) Ligand-binding pocket shape differences between sphingosine 1-phosphate (S1P) receptors S1P1 and S1P3 determine efficiency of chemical probe identification by ultrahigh-throughput screening. ACS Chem Biol 3:486–498. doi:10.1021/cb800051m
Sherman W, Day T, Jacobson MP et al (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553. doi:10.1021/jm050540c
Shivakumar D, Williams J, Wu Y et al (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509–1519. doi:10.1021/ct900587b
Siu FY, He M, de Graaf C et al (2013) Structure of the human glucagon class B G-protein-coupled receptor. Nature 499:444–449. doi:10.1038/nature12393
Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4:397–407. doi:10.1038/nrm1103
Takasugi N, Sasaki T, Suzuki K et al (2011) BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci 31:6850–6857. doi:10.1523/JNEUROSCI.6467-10.2011
Tan Q, Zhu Y, Li J et al (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341:1387–1390. doi:10.1126/science.1241475
Thompson AA, Liu W, Chun E et al (2012) Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485:395–399. doi:10.1038/nature11085
Urbano M, Guerrero M, Rosen H, Roberts E (2013) Modulators of the sphingosine 1-phosphate receptor 1. Bioorg Med Chem Lett. doi:10.1016/j.bmcl.2013.09.058
Vachal P, Toth LM, Hale JJ et al (2006) Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor. Bioorg Med Chem Lett 16:3684–3687. doi:10.1016/j.bmcl.2006.04.064
Valentine WJ, Kiss GN, Liu J et al (2010) (S)- FTY720-Vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. Cell Signal 22:1543–1553. doi:10.1016/j.cellsig.2010.05.023
Van Durme J, Horn F, Costagliola S et al (2006) GRIS: glycoprotein-hormone receptor information system. Mol Endocrinol 20:2247–2255. doi:10.1210/me.2006-0020
van Loenen PB, van Loenen PB, de Graaf C et al (2011) Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor. Eur J Pharmacol 667:105–112. doi:10.1016/j.ejphar.2011.05.071
Venkatakrishnan AJ, Deupi X, Lebon G et al (2013) Molecular signatures of G-protein-coupled receptors. Nature 494:185–194. doi:10.1038/nature11896
Visentin B, Vekich JA, Sibbald BJ et al (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225–238. doi:10.1016/j.ccr.2006.02.023
Vroling B, Sanders M, Baakman C et al (2011) GPCRDB: information system for G protein-coupled receptors. Nucleic Acids Res 39:D309–D319. doi:10.1093/nar/gkq1009
Wacker D, Wang C, Katritch V et al (2013) Structural features for functional selectivity at serotonin receptors. Science 340:615–619. doi:10.1126/science.1232808
Wang C, Jiang Y, Ma J et al (2013a) Structural basis for molecular recognition at serotonin receptors. Science 340:610–614. doi:10.1126/science.1232807
Wang C, Wu H, Katritch V et al (2013b) Structure of the human smoothened receptor bound to an antitumour agent. Nature 497:338–343. doi:10.1038/nature12167
Wang DA, Lorincz Z, Bautista DL et al (2001) A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J Biol Chem 276:49213–49220. doi:10.1074/jbc.M107301200
Warne T, Serrano-Vega MJ, Baker JG et al (2008) Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454:486–491. doi:10.1038/nature07101
Welch SP, Sim-Selley LJ, Selley DE (2012) Sphingosine-1-phosphate receptors as emerging targets for treatment of pain. Biochem Pharmacol 84:1551–1562. doi:10.1016/j.bcp.2012.08.010
Whetzel AM, Bolick DT, Srinivasan S et al (2006) Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 99:731–739. doi:10.1161/01.RES.0000244088.33375.52
White JF, Noinaj N, Shibata Y et al (2012) Structure of the agonist-bound neurotensin receptor. Nature 490:508–513. doi:10.1038/nature11558
Wu B, Chien EYT, Mol CD et al (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066–1071. doi:10.1126/science.1194396
Wu H, Wacker D, Mileni M et al (2012) Structure of the human κ-opioid receptor in complex with JDTic. Nature 485:327–332. doi:10.1038/nature10939
Xia P, Gamble JR, Wang L et al (2000) An oncogenic role of sphingosine kinase. Curr Biol 10:1527–1530. doi:10.1016/S0960-9822(00)00834-4
Xu H, McElvain M, Fiorino M et al (2013) Predictability of peripheral lymphocyte reduction of novel S1P1 agonists by in vitro GPCR signaling profile. J Biomol Screen. doi:10.1177/1087057113488629
Yan L, Huo P, Doherty G et al (2006) Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes. Bioorg Med Chem Lett 16:3679–3683. doi:10.1016/j.bmcl.2006.04.084
Yan L, Huo P, Hale JJ et al (2007) SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties. Bioorg Med Chem Lett 17:828–831. doi:10.1016/j.bmcl.2006.10.057
Zhang C, Srinivasan Y, Arlow DH et al (2012) High-resolution crystal structure of human protease-activated receptor 1. Nature 492:387–392. doi:10.1038/nature11701
Zhang H, Desai NN, Olivera A et al (1991) Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 114:155–167
Zipp F, Vollmer TL, Selmaj K, Bar-Or A (2012) Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, Phase II trial (DreaMS). ECTRIMS
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hanson, M.A., Peach, R. (2014). Structural Biology of the S1P1 Receptor. In: Oldstone, M., Rosen, H. (eds) Sphingosine-1-Phosphate Signaling in Immunology and Infectious Diseases. Current Topics in Microbiology and Immunology, vol 378. Springer, Cham. https://doi.org/10.1007/978-3-319-05879-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-05879-5_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-05878-8
Online ISBN: 978-3-319-05879-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)